BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

775 related articles for article (PubMed ID: 21856723)

  • 1. FET proteins TAF15 and EWS are selective markers that distinguish FTLD with FUS pathology from amyotrophic lateral sclerosis with FUS mutations.
    Neumann M; Bentmann E; Dormann D; Jawaid A; DeJesus-Hernandez M; Ansorge O; Roeber S; Kretzschmar HA; Munoz DG; Kusaka H; Yokota O; Ang LC; Bilbao J; Rademakers R; Haass C; Mackenzie IR
    Brain; 2011 Sep; 134(Pt 9):2595-609. PubMed ID: 21856723
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Transportin 1 accumulates specifically with FET proteins but no other transportin cargos in FTLD-FUS and is absent in FUS inclusions in ALS with FUS mutations.
    Neumann M; Valori CF; Ansorge O; Kretzschmar HA; Munoz DG; Kusaka H; Yokota O; Ishihara K; Ang LC; Bilbao JM; Mackenzie IR
    Acta Neuropathol; 2012 Nov; 124(5):705-16. PubMed ID: 22842875
    [TBL] [Abstract][Full Text] [Related]  

  • 3. FET proteins in frontotemporal dementia and amyotrophic lateral sclerosis.
    Mackenzie IR; Neumann M
    Brain Res; 2012 Jun; 1462():40-3. PubMed ID: 22261247
    [TBL] [Abstract][Full Text] [Related]  

  • 4. FUS is phosphorylated by DNA-PK and accumulates in the cytoplasm after DNA damage.
    Deng Q; Holler CJ; Taylor G; Hudson KF; Watkins W; Gearing M; Ito D; Murray ME; Dickson DW; Seyfried NT; Kukar T
    J Neurosci; 2014 Jun; 34(23):7802-13. PubMed ID: 24899704
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Nuclear carrier and RNA-binding proteins in frontotemporal lobar degeneration associated with fused in sarcoma (FUS) pathological changes.
    Davidson YS; Robinson AC; Hu Q; Mishra M; Baborie A; Jaros E; Perry RH; Cairns NJ; Richardson A; Gerhard A; Neary D; Snowden JS; Bigio EH; Mann DM
    Neuropathol Appl Neurobiol; 2013 Feb; 39(2):157-65. PubMed ID: 22497712
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Frontotemporal lobar degeneration and amyotrophic lateral sclerosis: molecular similarities and differences.
    Neumann M
    Rev Neurol (Paris); 2013 Oct; 169(10):793-8. PubMed ID: 24011641
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Transportin 1 colocalization with Fused in Sarcoma (FUS) inclusions is not characteristic for amyotrophic lateral sclerosis-FUS confirming disrupted nuclear import of mutant FUS and distinguishing it from frontotemporal lobar degeneration with FUS inclusions.
    Troakes C; Hortobágyi T; Vance C; Al-Sarraj S; Rogelj B; Shaw CE
    Neuropathol Appl Neurobiol; 2013 Aug; 39(5):553-61. PubMed ID: 22934812
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A comparative clinical, pathological, biochemical and genetic study of fused in sarcoma proteinopathies.
    Lashley T; Rohrer JD; Bandopadhyay R; Fry C; Ahmed Z; Isaacs AM; Brelstaff JH; Borroni B; Warren JD; Troakes C; King A; Al-Saraj S; Newcombe J; Quinn N; Ostergaard K; Schrøder HD; Bojsen-Møller M; Braendgaard H; Fox NC; Rossor MN; Lees AJ; Holton JL; Revesz T
    Brain; 2011 Sep; 134(Pt 9):2548-64. PubMed ID: 21752791
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Fused in sarcoma (FUS): an oncogene goes awry in neurodegeneration.
    Dormann D; Haass C
    Mol Cell Neurosci; 2013 Sep; 56():475-86. PubMed ID: 23557964
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Expression of Fused in sarcoma mutations in mice recapitulates the neuropathology of FUS proteinopathies and provides insight into disease pathogenesis.
    Verbeeck C; Deng Q; Dejesus-Hernandez M; Taylor G; Ceballos-Diaz C; Kocerha J; Golde T; Das P; Rademakers R; Dickson DW; Kukar T
    Mol Neurodegener; 2012 Oct; 7():53. PubMed ID: 23046583
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Requirements for stress granule recruitment of fused in sarcoma (FUS) and TAR DNA-binding protein of 43 kDa (TDP-43).
    Bentmann E; Neumann M; Tahirovic S; Rodde R; Dormann D; Haass C
    J Biol Chem; 2012 Jun; 287(27):23079-94. PubMed ID: 22563080
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The RNA-binding motif 45 (RBM45) protein accumulates in inclusion bodies in amyotrophic lateral sclerosis (ALS) and frontotemporal lobar degeneration with TDP-43 inclusions (FTLD-TDP) patients.
    Collins M; Riascos D; Kovalik T; An J; Krupa K; Krupa K; Hood BL; Conrads TP; Renton AE; Traynor BJ; Bowser R
    Acta Neuropathol; 2012 Nov; 124(5):717-32. PubMed ID: 22993125
    [TBL] [Abstract][Full Text] [Related]  

  • 13. An autopsy case of frontotemporal lobar degeneration with the appearance of fused in sarcoma inclusions (basophilic inclusion body disease) clinically presenting corticobasal syndrome.
    Matsumoto A; Suzuki H; Fukatsu R; Shimizu H; Suzuki Y; Hisanaga K
    Neuropathology; 2016 Feb; 36(1):77-87. PubMed ID: 26227957
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Stress granules in neurodegeneration--lessons learnt from TAR DNA binding protein of 43 kDa and fused in sarcoma.
    Bentmann E; Haass C; Dormann D
    FEBS J; 2013 Sep; 280(18):4348-70. PubMed ID: 23587065
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Heterogeneous nuclear ribonucleoproteins R and Q accumulate in pathological inclusions in FTLD-FUS.
    Gittings LM; Foti SC; Benson BC; Gami-Patel P; Isaacs AM; Lashley T
    Acta Neuropathol Commun; 2019 Feb; 7(1):18. PubMed ID: 30755280
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Monomethylated and unmethylated FUS exhibit increased binding to Transportin and distinguish FTLD-FUS from ALS-FUS.
    Suárez-Calvet M; Neumann M; Arzberger T; Abou-Ajram C; Funk E; Hartmann H; Edbauer D; Kremmer E; Göbl C; Resch M; Bourgeois B; Madl T; Reber S; Jutzi D; Ruepp MD; Mackenzie IR; Ansorge O; Dormann D; Haass C
    Acta Neuropathol; 2016 Apr; 131(4):587-604. PubMed ID: 26895297
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Gene expression responses to FUS, EWS, and TAF15 reduction and stress granule sequestration analyses identifies FET-protein non-redundant functions.
    Blechingberg J; Luo Y; Bolund L; Damgaard CK; Nielsen AL
    PLoS One; 2012; 7(9):e46251. PubMed ID: 23049996
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A new subtype of frontotemporal lobar degeneration with FUS pathology.
    Neumann M; Rademakers R; Roeber S; Baker M; Kretzschmar HA; Mackenzie IR
    Brain; 2009 Nov; 132(Pt 11):2922-31. PubMed ID: 19674978
    [TBL] [Abstract][Full Text] [Related]  

  • 19. O-GlcNAc glycosylation stoichiometry of the FET protein family: only EWS is glycosylated with a high stoichiometry.
    Kamemura K
    Biosci Biotechnol Biochem; 2017 Mar; 81(3):541-546. PubMed ID: 27903134
    [TBL] [Abstract][Full Text] [Related]  

  • 20. TDP-43 and FUS: a nuclear affair.
    Dormann D; Haass C
    Trends Neurosci; 2011 Jul; 34(7):339-48. PubMed ID: 21700347
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 39.